Alvotech Sets Sights On Stelara Submission By Close Of 2022
Company In Strong Position To Capitalize On Ustekinumab Opportunity
With positive data in hand, filings are set to follow • Source: Shutterstock (Andrii Yalanskyi / Alamy Stock P/Alamy Stock Photo) 
